Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 30;40(12):2783-2799.
doi: 10.1002/sim.8928. Epub 2021 Mar 16.

On the design and the analysis of stratified biomarker trials in the presence of measurement error

Susan Halabi  1 , Chen-Yen Lin  2 , Aiyi Liu  3
Affiliations

On the design and the analysis of stratified biomarker trials in the presence of measurement error

Susan Halabi et al. Stat Med. .

Abstract

A major emphasis in precision medicine is to optimally treat subgroups of patients who may benefit from certain therapeutic agents. And as such, enormous resources and innovative clinical trials designs in oncology are devoted to identifying predictive biomarkers. Predictive biomarkers are ones that will identify patients that are more likely to respond to specific therapies and they are usually discovered through retrospective analysis from large randomized phase II or phase III trials. One important design to consider is the stratified biomarker design, where patients will have their specimens obtained at baseline and the biomarker status will be assessed prior to random assignment. Regardless of their biomarker status, patients will be randomized to either an experimental arm or the standard of care arm. The stratified biomarker design can be used to test for a treatment-biomarker interaction in predicting a time-to event outcome. Many biomarkers, however, are derived from tissues from patients, and their levels may be heterogeneous. As a result, biomarker levels may be measured with error and this would have an adverse impact on the power of a stratified biomarker clinical trial. We present a trial design and an analysis framework for the stratified biomarker design. We show that the naïve test is biased and provide bias-corrected estimators for computing the sample size and the 95% confidence interval when testing for a treatment-biomarker interaction in predicting a time to event outcome. We propose a sample size formula that adjusts for misclassification and apply it in the design of a phase III clinical trial in renal cancer.

Keywords: biomarker; measurement error; precision medicine; randomized clinical trials; time-to-event endpoint.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
A Stratified Biomarker Design
FIGURE 2
FIGURE 2
Statistical Power for Various Combinations of Sensitivity and Specificity
FIGURE 3
FIGURE 3
Minimum Enrollment Length for Various Combinations of Sensitivity and Specificity
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Moscow JA, Fojo T, Schilsky RL. The evidence framework for precision cancer medicine. Nat Rev Clin Oncol. 2018; 15(3): 183–192. doi: 10.1038/nrclinonc.2017 - DOI - PubMed
    1. Hunter D, Longo D. The precision of evidence needed to practice “precision medicine”. N Eng J Med. 2019; 380(25): 2472–2474. doi: 10.1056/NEJMe1906088 - DOI - PubMed
    1. Halabi S, Niedzwiecki D. Advancing precision oncology through biomarker-driven trials: Theory vs. practice. Chance. 2019; 32: 23–31. doi: 10.1080/09332480.2019.1695438 - DOI
    1. Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC. Lung master protocol LungMAP: A biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin Cancer Res. 2015; 21(7): 1514–1524. doi: 10.1158/1078-0432.CCR-13-3473 - DOI - PMC - PubMed
    1. http://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-support.....

Publication types

LinkOut - more resources